China Stock Alerts
Stealth BioTherapeutics Corp.
NASDAQ:
MITO
Stealth BioTherapeutics Corp. is an innovative biopharmaceutical company developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases.
Stealth BioTherapeutics' mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Deloitte Touche Tohmatsu CPA LLP
IPO (February 15, 2019)
Cayman Islands
Newton, Massachusetts, USA
Janhavi Mohite, Stern IR
212-362-1200
Analyst Coverage
Latest News
May 28, 2021: Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference (yahoo.com)
May 18 2021: Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights (yahoo.com)
May 17, 2021: Stealth BioTherapeutics Announces Poster Presentation at American College of Cardiology (ACC) Annual Meeting (yahoo.com)
April 26, 2021: Stealth BioTherapeutics CEO to Give Keynote Presentation at Mitochondria-Targeted Drug Development Summit
April 6, 2021: Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights
April 1, 2021: Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021
March 16, 2021: Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer
March 2, 2021: Stealth BioTherapeutics to Present at Upcoming Investor Conferences in March
February 10, 2021: Stealth BioTherapeutics Announces Pricing Of $4.7 Million Registered Direct Offering Of American Depositary Shares
January 7, 2021: Stealth BioTherapeutics to Participate in Upcoming January Investor Conferences
January 6, 2021: Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As A Treatment For Cardiomyopathy In Barth Syndrome